Pages that link to "Q33392046"
Jump to navigation
Jump to search
The following pages link to Phase II study of sunitinib malate in patients with recurrent high-grade glioma. (Q33392046):
Displaying 50 items.
- Combining radiotherapy with sunitinib: lessons (to be) learned (Q26800587) (← links)
- Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date (Q26822717) (← links)
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme (Q26824557) (← links)
- Spinal cord tumours: advances in genetics and their implications for treatment (Q26851596) (← links)
- Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy (Q27320588) (← links)
- Angiogenic inhibition in high-grade gliomas: past, present and future (Q30455596) (← links)
- Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma (Q33396181) (← links)
- A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma (Q33402531) (← links)
- Continuous daily sunitinib for recurrent glioblastoma (Q33403947) (← links)
- A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). (Q33411920) (← links)
- MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy (Q33616649) (← links)
- Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma (Q33868524) (← links)
- Role of receptor tyrosine kinases and their ligands in glioblastoma (Q33883849) (← links)
- Response-predictive gene expression profiling of glioma progenitor cells in vitro (Q34277599) (← links)
- Glial progenitors as targets for transformation in glioma (Q34735661) (← links)
- Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. (Q35895174) (← links)
- Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro (Q35957639) (← links)
- Antiangiogenic therapy for glioma (Q36101999) (← links)
- A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma (Q36103026) (← links)
- Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas (Q36344757) (← links)
- A phase I/II trial of vandetanib for patients with recurrent malignant glioma (Q36401846) (← links)
- MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma (Q36580732) (← links)
- Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme (Q36713503) (← links)
- In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas (Q36723791) (← links)
- Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. (Q37094908) (← links)
- A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma (Q37201450) (← links)
- Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain (Q37331814) (← links)
- Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas (Q37407817) (← links)
- Immune-checkpoint blockade and active immunotherapy for glioma (Q37420586) (← links)
- Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. (Q37474359) (← links)
- Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging. (Q37725493) (← links)
- Role of tyrosine kinase inhibitors in the management of high-grade gliomas (Q37952242) (← links)
- Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? (Q37993124) (← links)
- Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions (Q38021521) (← links)
- Antiangiogenic therapy in the management of brain tumors: a clinical overview (Q38028766) (← links)
- Therapeutic targeting of VEGF in the treatment of glioblastoma (Q38033241) (← links)
- Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? (Q38062793) (← links)
- Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies. (Q38066416) (← links)
- Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date (Q38068203) (← links)
- Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach (Q38108186) (← links)
- Current status of antiangiogenic therapies for glioblastomas (Q38169761) (← links)
- Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment (Q38203283) (← links)
- Glioblastoma multiforme: State of the art and future therapeutics (Q38225874) (← links)
- State of the art and perspectives in the treatment of glioblastoma. (Q38233067) (← links)
- Glioblastoma targeted therapy: updated approaches from recent biological insights (Q38597700) (← links)
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib (Q38627885) (← links)
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials (Q38720644) (← links)
- AXL as a modulator of sunitinib response in glioblastoma cell lines (Q38914744) (← links)
- Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment (Q38933860) (← links)
- Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype (Q39281709) (← links)